Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 Next >
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
Tickers NTRA
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Issues Statement on Guardant Health Litigation
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Third Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Third Quarter 2024 Results on November 12, 2024
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Renasight Data at ASN Kidney Week 2024
From Natera, Inc.
Via Business Wire
Tickers NTRA
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
Tickers NTRA
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
Tickers NTRA
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.